Acadia Pharmaceuticals
ACAD
336 hedge funds and large institutions have $4.44B invested in Acadia Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 120 increasing their positions, 119 reducing their positions, and 43 closing their positions.
35% more call options, than puts
Call options by funds: $7.66M | Put options by funds: $5.68M
24% more capital invested
Capital invested by funds: $3.58B → $4.44B (+$863M)
23% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 43
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
1% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 119
1% more funds holding
Funds holding: 334 → 336 (+2)
1.06% less ownership
Funds ownership: 99.39% → 98.33% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$45.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$20.3M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$16.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$59.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$44.6M |
| 3 |
Citigroup
New York
|
-$35.6M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$28.7M |
| 5 |
Millennium Management
New York
|
-$22.2M |
ACAD Hedge Fund Activity: Q4 2025 in Review
336 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2025, worth a combined $4.44B — up 24% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ACAD positions and 43 closed out — a net gain of 10 holders — while 120 added to existing stakes and 119 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $45.2M. The largest seller was Adage Capital Partners, cutting an estimated $59.1M.
- 336 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2025, up from 334 in Q3 2025.
- Funds reported $4.44B of Acadia Pharmaceuticals stock for Q4 2025, up 24% quarter-over-quarter.
- 53 funds opened new Acadia Pharmaceuticals positions in Q4 2025 and 43 closed out, a net change of +10 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2025 was Point72 Asset Management, an estimated $45.2M added.
- The largest Acadia Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $59.1M sold.
Based on aggregated 13F filings for Q4 2025.